JP2021524249A5 - - Google Patents

Info

Publication number
JP2021524249A5
JP2021524249A5 JP2020565282A JP2020565282A JP2021524249A5 JP 2021524249 A5 JP2021524249 A5 JP 2021524249A5 JP 2020565282 A JP2020565282 A JP 2020565282A JP 2020565282 A JP2020565282 A JP 2020565282A JP 2021524249 A5 JP2021524249 A5 JP 2021524249A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
seq
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020565282A
Other languages
English (en)
Japanese (ja)
Other versions
JP7530299B2 (ja
JP2021524249A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/054188 external-priority patent/WO2019224717A2/en
Publication of JP2021524249A publication Critical patent/JP2021524249A/ja
Publication of JP2021524249A5 publication Critical patent/JP2021524249A5/ja
Priority to JP2024087232A priority Critical patent/JP2024116190A/ja
Application granted granted Critical
Publication of JP7530299B2 publication Critical patent/JP7530299B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565282A 2018-05-24 2019-05-21 抗ｃｄ３抗体及びその使用 Active JP7530299B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024087232A JP2024116190A (ja) 2018-05-24 2024-05-29 抗ｃｄ３抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862676081P 2018-05-24 2018-05-24
US62/676,081 2018-05-24
PCT/IB2019/054188 WO2019224717A2 (en) 2018-05-24 2019-05-21 Anti-cd3 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024087232A Division JP2024116190A (ja) 2018-05-24 2024-05-29 抗ｃｄ３抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2021524249A JP2021524249A (ja) 2021-09-13
JP2021524249A5 true JP2021524249A5 (enExample) 2022-05-25
JP7530299B2 JP7530299B2 (ja) 2024-08-07

Family

ID=67211773

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020565282A Active JP7530299B2 (ja) 2018-05-24 2019-05-21 抗ｃｄ３抗体及びその使用
JP2024087232A Pending JP2024116190A (ja) 2018-05-24 2024-05-29 抗ｃｄ３抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024087232A Pending JP2024116190A (ja) 2018-05-24 2024-05-29 抗ｃｄ３抗体及びその使用

Country Status (38)

Country Link
US (2) US11603405B2 (enExample)
EP (2) EP3802608B1 (enExample)
JP (2) JP7530299B2 (enExample)
KR (1) KR20210012007A (enExample)
CN (2) CN112912397B (enExample)
AR (1) AR115422A1 (enExample)
AU (1) AU2019274656B2 (enExample)
BR (1) BR112020023508A2 (enExample)
CA (1) CA3101271A1 (enExample)
CL (1) CL2020003033A1 (enExample)
CO (1) CO2020014506A2 (enExample)
CR (1) CR20200568A (enExample)
DK (1) DK3802608T3 (enExample)
EA (1) EA202092847A1 (enExample)
EC (1) ECSP20075215A (enExample)
ES (1) ES3032856T3 (enExample)
FI (1) FI3802608T3 (enExample)
HR (1) HRP20250621T1 (enExample)
HU (1) HUE072251T2 (enExample)
IL (1) IL278846A (enExample)
JO (1) JOP20200302A1 (enExample)
LT (1) LT3802608T (enExample)
MA (1) MA52773B1 (enExample)
MX (1) MX420253B (enExample)
NI (1) NI202000089A (enExample)
PE (1) PE20210132A1 (enExample)
PH (1) PH12020551920A1 (enExample)
PL (1) PL3802608T3 (enExample)
PT (1) PT3802608T (enExample)
RS (1) RS66901B1 (enExample)
SA (1) SA520420631B1 (enExample)
SG (1) SG11202011270QA (enExample)
SI (1) SI3802608T1 (enExample)
SM (1) SMT202500221T1 (enExample)
TW (1) TW202012443A (enExample)
UA (1) UA129050C2 (enExample)
UY (1) UY38245A (enExample)
WO (1) WO2019224717A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
MA52772A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
PE20211916A1 (es) 2018-05-24 2021-09-28 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MD3823665T2 (ro) 2018-07-19 2024-05-31 Regeneron Pharma Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
US11591395B2 (en) 2019-04-19 2023-02-28 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
BR112022001368A2 (pt) 2019-07-26 2022-05-24 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
EP4076523A1 (en) * 2019-12-18 2022-10-26 Janssen Biotech, Inc. Materials and methods for in vivo biological targeting
AU2021225870A1 (en) * 2020-02-27 2022-10-20 Janssen Biotech, Inc. Materials and methods for modulating an immune response
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
KR20230041819A (ko) 2020-07-29 2023-03-24 얀센 바이오테크 인코포레이티드 Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도
IL300835A (en) * 2020-09-02 2023-04-01 Genmab As Antibody therapy
MX2023003041A (es) 2020-09-16 2023-05-09 Amgen Inc Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
JP2023543826A (ja) * 2020-09-29 2023-10-18 イノベント バイオロジクス（シンガポール）プライベート リミティド 抗ｃｄ３抗体およびその使用
CA3199319A1 (en) 2020-10-22 2022-04-28 Janssen Biotech, Inc. Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
JP2024507180A (ja) * 2021-02-16 2024-02-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
CA3220913A1 (en) 2021-05-21 2022-11-24 Leo Pharma A/S Anti il-1 receptor accessory protein antibodies
AU2022333321A1 (en) * 2021-08-27 2024-04-11 Janssen Biotech, Inc. Anti-psma antibodies and uses thereof
US12600764B2 (en) * 2021-08-27 2026-04-14 International Business Machines Corporation Antigen-binding proteins targeting coronavirus (COV) variants
JP2025510266A (ja) * 2022-03-25 2025-04-14 嘉和生物▲薬▼▲業▼有限公司 Ｃｄ３を標的とする抗体及びその使用
AR130550A1 (es) * 2022-09-21 2024-12-18 Sanofi Biotechnology Anticuerpo anti-il-1r3 humanizado y métodos de uso
EP4598958A1 (en) 2022-10-05 2025-08-13 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024089551A1 (en) 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof
WO2024126833A1 (en) * 2022-12-16 2024-06-20 Ichnos Sciences SA Cd47-il1rap bispecific antibodies
WO2025134049A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
WO2025134050A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
TW202602940A (zh) 2024-04-09 2026-01-16 美商安進公司 激動性抗ｉｌ－２ｒｂｇ重鏈抗體
WO2025230233A1 (ko) * 2024-05-03 2025-11-06 국민대학교산학협력단 인간 cd3에 특이적인 항체 및 이의 용도
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof
WO2026078647A1 (en) 2024-10-11 2026-04-16 Janssen Biotech, Inc. Combination of trispecific antibody targeting bcma, gprc5d and cd3, and pomalidomide for the treatment of multiple myeloma
WO2026078659A1 (en) 2024-10-11 2026-04-16 Janssen Biotech, Inc. Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
PT1015576E (pt) 1997-09-16 2005-09-30 Egea Biosciences Llc Metodo para a sintese quimica completa e montagem de genes e de genomas
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
KR102060389B1 (ko) 2011-05-21 2019-12-31 마크로제닉스, 인크. 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
PT2931030T (pt) 2012-12-14 2020-08-03 Open Monoclonal Tech Inc Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem
ME03675B (me) * 2013-07-05 2020-10-20 Genmab As Humanizovana ili himerna anтi-cd3 antiтela
IL263466B2 (en) * 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
CN106459201A (zh) * 2014-05-28 2017-02-22 豪夫迈·罗氏有限公司 结合人和食蟹猴CD3ε的抗体
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
CN120988137A (zh) * 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
EA201891084A1 (ru) 2015-11-02 2019-10-31 Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
PE20241349A1 (es) 2016-09-14 2024-07-03 Teneobio Inc Anticuerpos de union a cd3
UA130542C2 (uk) * 2018-05-16 2026-03-18 Янссен Байотек, Інк. Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта
PE20211916A1 (es) 2018-05-24 2021-09-28 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
MA52772A (fr) * 2018-05-24 2021-04-14 Janssen Biotech Inc Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations

Similar Documents

Publication Publication Date Title
JP2021524249A5 (enExample)
FI3802608T3 (fi) Cd3-vasta-aineita ja niiden käyttötapoja
JP2023113893A5 (enExample)
JP2020103301A5 (enExample)
JP2020520370A5 (enExample)
JP2021531764A5 (enExample)
JP2021531005A5 (enExample)
JP2020501531A5 (enExample)
JP2022509065A5 (enExample)
JP2023543152A5 (enExample)
JP2022510964A5 (enExample)
JP2020528750A5 (enExample)
JP2018534933A5 (enExample)
AU2018268304A1 (en) Anti-SIRPα antibodies
FI3618863T3 (fi) Anti-TIGIT-vasta-aineita ja menetelmiä niiden käyttämiseksi
RU2010129045A (ru) Связывающие молекулы к рецептору ох40 человека
JP2022533538A5 (enExample)
JP2022525071A5 (enExample)
JP2023518153A5 (enExample)
JP2022545741A5 (enExample)
IL272770B1 (en) CD40 agonist antibodies
RU2017114968A (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
JP2021520201A5 (enExample)
JP2021524255A5 (enExample)
JP2024538669A5 (enExample)